LYRM2

Across TCGA pan-cancer cohorts, LYRM2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LYRM2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LYRM2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYRM2 expression acts as an unfavorable survival marker.

UCEC and LUSC are the cancer types where LYRM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	0.224	0.768	.005	12	view →
LUSC	DFS	Median	All	0.174	0.645	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LYRM2–UCEC (OS)

Open the UCEC breakdown →